Orexo ABOSTO:ORX +0.22%49 EBITDA Margin % is -1,322.00% as of Mar. 2026. GuruFocus rates OSTO:ORX with a GF Score™ of 49/100 and a GF Value™ of kr6.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Orexo AB ranks worse than 90.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Orexo AB's EBITDA for the
three
months ended in Mar. 2026 was kr-66.1 Mil. Orexo AB's Revenue for the
three
months ended in Mar. 2026 was kr5.0 Mil. Therefore, Orexo AB's EBITDA margin for the quarter that ended in Mar. 2026 was -1,322.00%.
Orexo AB (OSTO:ORX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Orexo AB EBITDA Margin % Related Terms
Orexo AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Orexo AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Orexo AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orexo AB (OSTO:ORX) has a EBITDA Margin % of -1,322.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Orexo AB and its competitors. According to the industry distribution chart, Orexo AB ranks #862 out of 955 companies in the Drug Manufacturers industry, placing it in the top 90.3%.
Is Orexo AB's EBITDA Margin % too high?
Orexo AB's current EBITDA Margin % is -1,322.00%. Based on the distribution chart, Orexo AB ranks #862 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orexo AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #862 out of 955 companies for EBITDA Margin %. This places Orexo AB in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current EBITDA Margin % is -1,322.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (OSTO:ORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.45, compared to a current price of kr22.55 — trading 249.6% above its estimated fair value. The current EBITDA Margin % is -1,322.00%. Orexo AB's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Orexo AB (OSTO:ORX), the current EBITDA Margin % is -1,322.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (OSTO:ORX) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of kr22.55 is trading 249.6% above its estimated GF Value™ of kr6.45.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for OSTO:ORX:
EBITDA Margin %: -1,322.00%
GF Value™: kr6.45 vs. price of kr22.55 (249.6% above fair value)
No single metric tells the full story. See the OSTO:ORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
49GF Score
Get the complete analysis for OSTO:ORX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ORX has been successfully added to your 
